MarketCapExport financials
Cardiovascular Systems (CSII)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Cardiovascular Systems Income Statement 2022-2009 | CSII
Brief overview of revenue and earnings at Cardiovascular Systems
The comparison covers a five-year financial horizon. The revenue attributed to Cardiovascular Systems moved from $52.6 million to $236 million between the two endpoints. The cumulative result was +348.9%, corresponding to roughly 35% per year. Sales grew at a rate typical of a strong expansion phase.
At the gross-profit level, the result moved from 43.1 million dollars to 173 million dollars, a change of +300.6%. Direct costs grew more slowly than revenue and improved the economics of sales. At the margin level, the figure shifted from 82% to 73.1%. Weakening gross profitability reduces the quality of the top-line trend.
EBITDA was $2.4 million at the beginning and −$32.1 million at the end of the period (−1452.4%). Changes in revenue did not translate into comparable EBITDA performance. Comparing the endpoints gives EBITDA margins of 4.5% and −13.6%. Operating return per unit of revenue declined.
The final result was −$413 thousand initially and −$36.9 million in the final year. The period ended with a larger loss than it began with.
The market value of the business moved from $770 million to $602 million, or −21.8%. Financial performance is stronger than the share-price trend.
Summary assessment
The current trajectory does not yet confirm a sustainable recovery. The constructive conclusion rests on a larger revenue base. The weaker side of the profile includes weaker operating efficiency, declining capitalization and pressure from direct costs. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
602 M | 818 M | 1.42 B | 1.26 B | 1.17 B | 770 M | 924 M | 264 M | 1.07 B | 759 M | 285 M | 144 M | - | - |
Shares |
39.2 M | 38.8 M | 34.3 M | 33.5 M | 33.1 M | 32.4 M | 32.5 M | 31.5 M | 28.3 M | 21.7 M | 18 M | 15.9 M | 14.7 M | - |
Historical Prices |
15.3 | 21.1 | 41.3 | 37.6 | 35.4 | 23.8 | 28.4 | 8.36 | 37.7 | 35 | 15.8 | 9.05 | - | - |
Net Income |
-36.9 M | -13.4 M | -27.2 M | -255 K | 492 K | -413 K | 1.04 M | -15.2 M | -5.27 M | -8.66 M | -5.77 M | -11.1 M | -23.9 M | - |
Revenue |
236 M | 259 M | 237 M | 248 M | 60.2 M | 52.6 M | 178 M | 182 M | 137 M | 104 M | 82.5 M | 78.8 M | - | - |
Cost of Revenue |
63.4 M | 61.1 M | 48.8 M | 47.7 M | 39.5 M | 39.4 M | - | - | - | - | - | - | - | - |
Gross Profit |
173 M | 198 M | 188 M | 200 M | 48.7 M | 43.1 M | 40.9 M | 33.3 M | 35.4 M | 25 M | 19.4 M | 62.5 M | 49.8 M | - |
Operating Income |
-35.8 M | -11.9 M | -26.8 M | -825 K | 2.23 M | -1.54 M | -56.1 M | -32.6 M | -33.5 M | -22.4 M | -14.5 M | -8.81 M | -22.9 M | - |
Interest Expense |
1.63 M | 1.74 M | 1.97 M | 1.68 M | 1.72 M | 500 K | - | 23 K | 1.03 M | 1.34 M | 1.36 M | 1.42 M | 1.44 M | - |
EBITDA |
-32.1 M | -8.84 M | -23.8 M | 2.32 M | 5.96 M | 2.38 M | -52.4 M | -30.5 M | -32.2 M | -22.3 M | -14.4 M | -8.76 M | -22.8 M | - |
Operating Expenses |
209 M | 210 M | 215 M | 201 M | 175 M | 167 M | 199 M | 175 M | 139 M | 102 M | 77.7 M | 71.3 M | 72.7 M | - |
General and Administrative Expenses |
171 M | 167 M | 170 M | 168 M | 149 M | 144 M | 163 M | 144 M | 118 M | 86.7 M | 66.4 M | 62.4 M | 62.4 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Cardiovascular Systems
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
39.7 M | 39.6 M | 39.7 M | 39.3 M | 39.2 M | 39.1 M | 39.2 M | 39.1 M | 38.9 M | 38.9 M | 38.8 M | 38.7 M | 34.1 M | 33.9 M | 34.1 M | 33.6 M | 33.5 M | 33.4 M | 33.5 M | 33.2 M | 33.1 M | 33 M | 33.1 M | 32.7 M | 32.2 M | 33 M | 32.2 M | 32.7 M | 32.6 M | 32.2 M | 32.6 M | 31.6 M | 31.5 M | 31.3 M | 31.5 M | 30.4 M | 27.2 M | 24.8 M | 27.2 M | 21.5 M | 20.7 M | 20.4 M | 20.7 M | 18 M | 17.9 M | 17.7 M | 17.8 M | 17.5 M | 17 M | 17 M |
Net Income |
-7.89 M | -10.6 M | -7.89 M | -9.66 M | -8.97 M | -8.62 M | -8.97 M | -8.62 M | -6 M | -8.62 M | -56 K | -2.08 M | -3.4 M | -5.78 M | -3.4 M | 672 K | 492 K | -2.89 M | 492 K | 365 K | -413 K | -1.98 M | -413 K | -1.75 M | 1.04 M | -1.86 M | 1.04 M | -22.7 M | -15.2 M | -13.3 M | -15.2 M | -10.7 M | -5.27 M | -8.22 M | -5.27 M | -9.71 M | -8.66 M | -7.29 M | -8.66 M | -6.22 M | -5.77 M | -5.21 M | -5.77 M | -4.19 M | -4.14 M | -3.86 M | -4.14 M | -3.86 M | -4.14 M | -3.86 M |
Revenue |
61.5 M | 59.7 M | 61.5 M | 56.2 M | 59.1 M | 58.4 M | 59.1 M | 58.4 M | 63.3 M | 63.3 M | 64.2 M | 60.5 M | 68.3 M | 64.5 M | 68.3 M | 63.3 M | 60.2 M | 56.3 M | 60.2 M | 56.3 M | 60.2 M | 56.3 M | 52.6 M | 49.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
18.5 M | 16.7 M | 18.5 M | 14.8 M | 18.1 M | 14.3 M | 18.1 M | 14.3 M | 14 M | 14 M | 13.9 M | 12.6 M | 13.7 M | 12.7 M | 13.7 M | 12.2 M | 11.5 M | 10.6 M | 11.5 M | 10.6 M | 11.5 M | 10.6 M | 9.5 M | 9.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
43 M | 43 M | 43 M | 41.4 M | 41.1 M | 44.1 M | 41.1 M | 44.1 M | 49.3 M | 49.3 M | 50.2 M | 48 M | 54.6 M | 51.8 M | 54.6 M | 51.1 M | 48.7 M | 45.7 M | 48.7 M | 45.6 M | 43.1 M | 40.5 M | 43.1 M | 41 M | 40.9 M | 40.3 M | 40.9 M | 35.7 M | 33.3 M | 35.1 M | 33.3 M | 36.6 M | 35.4 M | 32.5 M | 35.4 M | 27.2 M | 25 M | 22.9 M | 25 M | 20.2 M | 19.4 M | 18 M | 19.4 M | 16.1 M | 15.2 M | 14.3 M | 15.2 M | 14.3 M | 15.2 M | 14.3 M |
Operating Income |
-8.53 M | -10.9 M | -8.53 M | -9.65 M | -8.56 M | -8.12 M | -8.56 M | -8.12 M | -5.65 M | -5.65 M | 283 K | -1.66 M | -3.37 M | -5.93 M | -3.37 M | 507 K | 384 K | -2.97 M | 384 K | 489 K | -275 K | -1.75 M | -275 K | -1.76 M | 1.08 M | -1.87 M | 1.08 M | -22.7 M | -15.1 M | -13.2 M | -15.1 M | -10.5 M | -5.25 M | -8.19 M | -5.25 M | -9.59 M | -7.5 M | -6.85 M | -7.5 M | -5.41 M | -5.12 M | -5.21 M | -5.12 M | -3.72 M | -3.66 M | -3.1 M | -3.66 M | -3.1 M | -3.66 M | -3.1 M |
Interest Expense |
404 K | 406 K | 404 K | 408 K | 409 K | 410 K | 409 K | 410 K | 412 K | 412 K | 412 K | 499 K | 500 K | 472 K | 500 K | 420 K | 422 K | 424 K | 422 K | 429 K | 430 K | 432 K | 430 K | 432 K | 430 K | 432 K | 46 K | - | - | - | - | 1 K | 6 K | 16 K | 6 K | 103 K | 564 K | 281 K | 564 K | 327 K | 345 K | 370 K | 345 K | 370 K | 345 K | 370 K | 279 K | 344 K | - | - |
EBITDA |
-6.73 M | -10 M | -8.18 M | -6.81 M | -6.66 M | -7.16 M | -8.21 M | -7.16 M | -3.42 M | -5.34 M | 587 K | -933 K | -1.88 M | -5.19 M | -3.04 M | 2.89 M | 1.96 M | -2.17 M | 439 K | 3.42 M | 1.71 M | -758 K | -275 K | 1.17 M | 3.02 M | -910 K | 1.08 M | -20 M | -13.3 M | -12.3 M | -15.1 M | -9.25 M | -4.5 M | -7.82 M | -5.25 M | -9.46 M | -7.39 M | -6.82 M | -7.5 M | -5.27 M | -5.02 M | -5.18 M | -5.12 M | -3.68 M | -3.66 M | -3.1 M | -3.66 M | -3.06 M | -3.66 M | -3.1 M |
Operating Expenses |
51.5 M | 53.9 M | 51.5 M | 51.1 M | 49.6 M | 52.2 M | 49.6 M | 52.2 M | 54.9 M | 54.9 M | 50 M | 49.6 M | 58 M | 57.8 M | 58 M | 50.6 M | 48.3 M | 48.7 M | 48.3 M | 45.1 M | 43.4 M | 42.2 M | 43.4 M | 42.8 M | 39.8 M | 42.2 M | 39.8 M | 58.5 M | 48.5 M | 48.3 M | 48.5 M | 47.1 M | 40.6 M | 40.7 M | 40.6 M | 36.8 M | 32.5 M | 29.7 M | 32.5 M | 25.6 M | 24.5 M | 23.2 M | 24.5 M | 19.8 M | 18.8 M | 17.4 M | 18.8 M | 17.4 M | 18.8 M | 17.4 M |
General and Administrative Expenses |
41.6 M | 44.5 M | 41.6 M | 41.7 M | 40.4 M | 41.9 M | 40.4 M | 41.9 M | 41.4 M | 41.4 M | 40.1 M | 40.3 M | 46.9 M | 46.8 M | 46.9 M | 41.4 M | 41.1 M | 41.2 M | 41.1 M | 37.8 M | 37 M | 35.9 M | 37 M | 37.3 M | 34 M | 36.9 M | 34 M | 42.3 M | 41.3 M | 41.4 M | 41.3 M | 39.4 M | 32.6 M | 33.5 M | 32.6 M | 31.4 M | 27.5 M | 25.4 M | 27.5 M | 21.6 M | 20.4 M | 20 M | 20.4 M | 16.8 M | 15.7 M | 15.4 M | 15.7 M | 15.4 M | 15.7 M | 15.4 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Cardiovascular Systems (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B |  USA |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |
 |
SmileDirectClub
SDC
|
- | -53.45 % | $ 9.71 M | USA |
 |
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | USA |
 |
CONMED Corporation
CNMD
|
$ 47.96 | -2.48 % | $ 1.49 B | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
ClearPoint Neuro
CLPT
|
$ 9.05 | -1.04 % | $ 256 M | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | USA |
 |
Delcath Systems
DCTH
|
$ 14.66 | 1.66 % | $ 525 M | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
- | 0.28 % | $ 270 M | USA |
 |
Zynex
ZYXI
|
- | - | $ 21.1 M | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M |  Israel |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Globus Medical
GMED
|
$ 81.12 | -0.36 % | $ 11 B | USA |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
Neovasc
NVCN
|
- | - | $ 111 M |  Canada |
 |
Invacare Corporation
IVC
|
- | - | $ 24.7 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 12.07 | 1.34 % | $ 925 M | USA |
 |
InMode Ltd.
INMD
|
$ 13.77 | -1.43 % | $ 890 M | Israel |
 |
Apyx Medical Corporation
APYX
|
$ 2.41 | 1.69 % | $ 99 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.12 | -4.69 % | $ 14.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 85.76 | -0.12 % | $ 1.09 B | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 126.54 | -0.01 % | $ 4.4 B | USA |
 |
Inogen
INGN
|
$ 7.05 | -0.77 % | $ 188 M | USA |
 |
Bruker Corporation
BRKR
|
$ 57.98 | 0.68 % | $ 8.8 B | USA |
 |
Boston Scientific Corporation
BSX
|
$ 45.24 | -0.91 % | $ 67 B | USA |
 |
LivaNova PLC
LIVN
|
$ 79.76 | -1.41 % | $ 4.35 B | Britain |
 |
Pulmonx Corporation
LUNG
|
$ 1.96 | 7.1 % | $ 79.7 M | USA |
 |
Medtronic PLC
MDT
|
$ 94.3 | -1.14 % | $ 121 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 4.26 | -19.26 % | $ 265 M | USA |
 |
Myomo
MYO
|
$ 1.2 | -1.64 % | $ 50.2 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.35 | -4.75 % | $ 22.7 M | Israel |
 |
InspireMD
NSPR
|
$ 0.47 | 3.69 % | $ 30.2 M | Israel |
 |
Outset Medical
OM
|
$ 4.07 | -0.85 % | $ 61.9 K | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
- | - | $ 1.77 B | USA |
 |
PAVmed
PAVM
|
$ 2.26 | 4.15 % | $ 1.52 M | USA |
 |
Penumbra
PEN
|
$ 324.88 | 0.05 % | $ 12.6 B | USA |
 |
Insulet Corporation
PODD
|
$ 147.21 | -1.21 % | $ 10.4 B | USA |
 |
Lianluo Smart Limited
LLIT
|
- | 24.59 % | $ 44.8 M |  China |
 |
Obalon Therapeutics, Inc.
OBLN
|
- | -5.86 % | $ 30.6 M | USA |
 |
AVITA Medical
RCEL
|
$ 15.23 | -1.8 % | $ 424 M |  Australia |
 |
Inspire Medical Systems
INSP
|
$ 70.62 | -0.58 % | $ 2.07 B | USA |
 |
Sintx Technologies
SINT
|
$ 1.61 | 1.9 % | $ 4.47 M | USA |